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ABSTRACT
Background and aim: The durability of the sustained virologic response (SVR) in patients with 
chronic hepatitis C after treatment and the ideal follow-up time for these patients remains unde-
fi ned. The objective of the study was to evaluate the durability of the virologic response in patients 
with chronic hepatitis C followed up for at least 12 months after SVR at HCFMRP-USP. Methods: 
The study was conducted on 174 patients with chronic hepatitis C treated with different antiviral 
regimens who had achieved SVR. Qualitative serum HCV-RNA was determined by the commercial 
kit (COBAS AMPLICOR HCV, v2.0). Results: There was predominance of male (73%) with a mean 
age of 45.6 ± 10 years. Liver cirrhosis was present in 16.1% of the study subjects. Mean follow-up 
time after SVR was 47 months (12-156 months). Twenty-two patients received monotherapy with 
interferon; 94 received interferon plus ribavirin, and 58 received pegylated interferon plus ribavirin. 
A total of 134 patients (77.0%) received one treatment course, 29 (16.7%) received two courses, 
and 11 (6.3%) received three courses. The distribution of HCV genotypes was: genotype 1 (40.2%), 
genotype 3 (40.8%) and genotype 2 (10.3%). Genotype was undetermined in 8.7% of cases. None 
of the 174 patients had recurrence of HCV infection. Two cirrhotic patients developed hepatocel-
lular carcinoma (HCC) during follow-up. Conclusions: Among patients with SVR there was no 
recurrence of HCV infection or evidence of liver disease progression in any patient followed up for 
a mean of 47 months after SVR, except for patients with advanced hepatic disease before treatment, 
who may develop HCC despite SVR. Therefore, one can assume that SVR is associated with long 
term good prognosis.
Keywords: hepatitis C, interferon, HCV, follow-up, hepatocellular carcinoma.
[Braz J Infect Dis 2010;14(4):330-334]©Elsevier Editora Ltda.
INTRODUCTION
Hepatitis C virus (HCV) is currently recog-
nized as the major cause of chronic liver dis-
ease worldwide. HCV infects 2.2% to 3% of the 
world population with a total of 130 million 
chronic carriers that differ in terms of potential 
progression to liver cirrhosis and hepatocellu-
lar carcinoma (HCC).1,2 
The main objective of treatment of chronic 
HCV infection is to prevent disease progression 
to more severe forms and to improve patient sur-
vival and quality of life. Thus far, interferon (IFN) 
alpha, initially administered as monotherapy and 
later combined with ribavirin (RBV), is the only 
effective regimen for the treatment of chronic 
HCV infection.3 Currently, the combination 
of pegylated IFN and RBV is the treatment of 
choice for chronic HCV infection.4,5
Treatment effi cacy is assessed by the sus-
tained virologic response (SVR), which is de-
fi ned by undetectable HCV-RNA six months 
after the end of therapy.6
Several controlled studies have demonstrat-
ed increasing SVR rates. SVR rates of 6% to 20% 
have been reported with the use of conventional 
IFN monotherapy, and 42%-82% rates have 
been reported with the use of pegylated IFN plus 
RBV.1,7-10 The results of combined pegylated IFN 
and RBV therapy vary according to HCV geno-
type, with SVR rates of 42% to 50% in patients 
infected with genotype 1, and of 80% in patients 
infected with genotype 2 or 3.1,2,6
Studies have demonstrated that SVR is associ-
ated with histological improvement, assessed by 
liver biopsy, and with the prevention of compli-
cations, such as the development of liver cirrho-
sis and HCC.11-14 Thus, SVR as result of therapy 
is deemed as an important factor for long-term 
favourable prognosis, although 4.0% to 8.7% of 
late recurrence was observed in two studies.10,15 
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In addition, some clinical studies have indicated the occur-
rence of HCC cases in cirrhotic patients who had developed 
SVR after antiviral treatment, emphasizing the need to main-
tain HCC screening regardless of treatment response.11,16-19
Despite favourable good long-term prognosis for patients 
with SVR, the durability of SVR and the optimal length of fol-
low-up for these patients is still open to controversy.10,14,16,18-20
Thus, the objective of the present study was to determine 
the durability of SVR in chronic HCV patients treated with dif-
ferent forms of IFN, either in monotherapy or in combination 
with RBV, and followed up for at least 12 months after SVR, re-
ceiving care at the Hepatitis Outpatient Clinic of the University 
Hospital, Faculdade de Medicina de Ribeirão Preto, Universi-
dade de São Paulo (HCFMRP-USP) from 1994 to 2007.
 
MATERIAL AND METHODS
Clinical and laboratory data and liver biopsies of 174 pa-
tients known to have developed SVR after therapy with dif-
ferent forms of IFN monotherapy or IFN combined with 
RBV were eligible for the study. Before antiviral treatment, 
all patients had serum positivity for HCV-RNA determined 
by the polymerase chain reaction (PCR) (commercial CO-
BAS AMPLICOR HCV method, v2.0, Roche Molecular Sys-
tems, Branchburg, USA) and elevated ALT on at least one 
occasion (> 1.5 X Upper Limit of Normal). HCV genotype 
was determined in all patients by the InnoLiPA assay (IN-
NOLIPA, Versant TM HCV Genotype Assay, LiPA, Mfd In 
Belgium for Bayer Corporation, Tarrytown, NY 10591-5097 
USA). Patients co-infected with HIV or hepatitis B (HBV), 
and individuals affected by other chronic liver diseases in 
addition to HCV were excluded. A liver biopsy was available 
for 166 patients (95.4%) before antiviral treatment.
Liver biopsies, performed under real time ultrasound guid-
ance using a Trucut 14G needle, were reported according to 
the necro-inﬂ ammatory activity (HAI scores 0 to 18) and to 
the stage of liver fi brosis (scores 0 to 4) using the classifi cation 
of Knodell et al. (1981),21 modifi ed by Desmet et al. (1994).22 
Dose and duration of administered antiviral therapy were 
based on international recommendations at the time of treat-
ment indication.3,5,7-9 Interferon alpha 2a or alpha 2b was used 
as standard interferon (3 million units 3 times a week for 24 or 
48 weeks) and pegylated interferon was used at weekly doses of 
180 µg/kg (alpha 2a) or 1.5 µg/kg (alpha 2b) for 48 weeks.
SVR was defi ned as HCV-RNA negativity six months after 
the end of therapy, as determined by commercial kits (CO-
BAS AMPLICOR HCV v2.0; sensitivity limit of 50 IU/mL). 
Ever since SVR was established, all patients were annually 
tested for serum HCV-RNA. In addition, cirrhotic patients 
were also evaluated every six months for liver tests (bilirubin, 
prothrombin time, albumin and liver enzymes) and screening 
for HCC (liver ultrasound and serum alpha-fetoprotein).
Length of SVR was determined as the time elapsed from the 
date SVR had been established and the date of the latest quali-
tative negative HCV-RNA test. Patients with a SVR length less 
than 12 months were excluded from the study.
 
RESULTS
There was predominance of male (73%) and caucasian (88.5%), 
with a mean patient age of 45.6 ± 10 years. Liver cirrhosis was 
present in 28 (16.1%) patients. Mean follow-up time after SVR 
was of 47 months (range: 12 to 156 months). 
The main patient characteristics according to the used 
therapeutic regimen for treating HCV infection are summa-
rized in Table 1.
Table 1. Baseline patient characteristics and pretreatment liver histology of 174 patients with chronic 
hepatitis C according to antiviral regimens
Characteristics Interferon Interferon + ribavirin Peginterferon + ribavirin
  (n = 22) (n = 94) (n = 58)
Gender (M/F) 17/5 69/25 41/17
Mean age (years) 42.3 ± 11.3 46.2 ± 10.3 44.7 ± 9.8
Sources of HCV infection       
 Intravenous drug user (n = 21)  3 (13.6%) 10 (10.6%) 8 (13.7%)
 Blood transfusion (n = 31) 2 (9.0%) 15 (15.9%) 14 (24.1%)
 Others† (n = 85) 14 (63.6%) 54 (57.4%) 17 (29.3%)
 Unknown (n = 66) 9 (40.9%) 25 (26.5%) 32 (55.1%)
Liver biopsy‡      
 F0/F1 (n = 71) 13 (81.2%) 38 (40.9%) 20 (35.1%)
 F2 (n = 67) 1 (6.3%) 35 (37.6%) 31 (54.4%)
 F3/F4 (n = 28) 2 (12.5%) 20 (21.5%) 6 (10.5%)
†Occupational hazard, inhalatory illicit drug use, parenteral fortifiers, tattoo.
n – number of patients.
‡Grade of fibrosis [Knodell et al. (1981),21 modified by Desmet et al. (1994)].22
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Twenty-two patients received IFN alpha–2a or 2b 
monotherapy, 152 received combined therapies (IFN al-
pha 2a or 2b plus RBV in 94 cases and PEG-IFN alpha 
2a or 2b plus RBV in 58). A total of 104 patients (77%) 
received one treatment course, 29 (16.7%) received two 
coursess, and 11 (6.3%) received three courses. 
HCV genotype 1 was found in 70 patients (40.2%), 
genotype 2 in 18 patients (10.3%), and genotype 3 in 
71 (40.8%). In 15 patients (8.7%) the genotype was not 
identified.
In 28 out of 174 patients with SVR (16.1%), the di-
agnosis of liver cirrhosis was established before the be-
ginning of treatment. In this group there was also pre-
dominance of males (82.1%) and caucasians (92.9%). 
Two patients were treated with IFN monotherapy and 
26 received combined therapy (IFN in combination with 
RBV in 20 cases and PEG IFN in combination with RBV 
in 6 cases).Twenty-three patients (82.1%) received one 
treatment course, 3 patients (10.7%) received two cours-
es, and 2 patients (7.1%) received three courses. In this 
group, the infecting HCV was of genotype 1 in 28.5%, 
genotype 2 in 10.7%, and genotype 3 in 53.5%; genotype 
was not identified in 7.3%. None of the 28 cirrhotic pa-
tients presented decompensation of liver disease during a 
mean follow-up period of 38.5 months (range: 12 to 109 
months). Screening for HCC (liver ultrasound and de-
termination of alpha-fetoprotein every six months) was 
performed in all patients of this group, with HCC being 
detected in two patients – after 22 months of SVR in one, 
and after 64 months of SVR in the other. None of them 
had detectable serum HCV-RNA at the time of HCC di-
agnosis. The characteristics of these patients are shown 
in Table 2.
There was no recurrence of HCV infection in any of 
the 174 patients with SVR followed up for more than 12 
months after SVR. 
DISCUSSION
In the present series SVR was maintained in all cases over 
a mean period of observation of 47 months (range: 12 to 
156 months). These data confi rm results reported in other 
studies showing 92% to 100% rates of undetectable HCV-
RNA after treatment with different forms of IFN, alone or in 
combination with RBV, over a mean follow-up period of 1 
to 12 years.10,13,14,16,18-20,23
A key question in the long-term management and fol-
low-up of patients with SVR is the durability of the response 
and the extent to which it results in permanent disease re-
mission. Late relapse rates of 0% to 9% after SVR have been 
reported in some studies. It should be pointed out that these 
studies involved different periods of follow-up, varying 
defi nitions of biochemical and virologic response, as well as 
PCR tests with different sensitivity thresholds for the detec-
tion of HCV-RNA.10,13,15,20,24 Such variability was of limited 
utility to guide clinicians about the ideal length of follow-up 
of treated patients with chronic hepatitis C who achieved 
SVR after antiviral treatment.
Desmond et al.10 evaluated the durability of SVR in 147 
patients receiving different treatment regimens (IFN mono-
therapy in 34, IFN plus RBV in 76, and Peg IFN plus RBV in 
37) and followed up for a mean period of 2.3 years (range: 
0.3 to 10.3 years). During this period, 146/147 patients 
(> 99%) showed no virologic recurrence. Swain et al.25 evalu-
ated the durability of SVR after treatment with pegylated IFN 
alpha 2a, either combined or not with RBV, in 845 patients 
from different studies. Only seven patients (1%) showed de-
tectable serum HCV-RNA after a mean time of 391 to 1076 
days of follow-up. These data emphasize that a relapse after 
obtaining SVR in patients with chronic hepatitis C treated 
with different forms of IFN is a rare occurrence.
Some studies have shown that serum HCV-RNA nega-
tivity results in similar changes in intrahepatic HCV-RNA.26 
Table 2. Patient characteristics and laboratory features of the two patients with cirrhosis and SVR who 
developed HCC during follow-up 
Characteristics Case 1 Case 2
Age (years) 64 53
Gender Female Male
HCV Genotype Unidentified 3
Previous liver cirrhosis Yes Yes
Time after SVR (months)† 64 22
Alpha fetoprotein (ng/mL) 242 4.20
Lesion size (cm)‡ 5.5 2.0
†Time after SVR when HCC was first detected.
‡Evaluated by liver ultrasound.
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However, it is still being questioned whether negativity of 
serum HCV-RNA induced by antiviral treatment results in 
complete elimination of HCV or whether the virus persists 
in small amounts in the hepatocytes. In studies in which less 
sensitive assays (sensitivity of 1000 copies/mL) were used for 
the detection of HCV RNA in serum, approximately 95% 
of the patients with SVR did not present detectable hepatic 
HCV-RNA during a follow-up period of 1 to 2 years after the 
end of treatment.13,26-28 However, despite serum HCV-RNA 
negativity, patients may occasionally present low levels of 
detectable virus in the liver tissue. This condition has been 
demonstrated to be a predictor of high probability of later re-
currence of HCV infection.26
SVR following antiviral treatment can translate into im-
provement of liver histology, thus preventing progression 
to more severe forms of disease12,13,16 and to development of 
HCC.11 However, even though SVR prevents progression of 
liver disease to cirrhosis, there is a risk of developing HCC in 
patients who already have cirrhosis at the time of treatment 
initiation.16-19,29,30 The effects of HCV-RNA, even at low levels, 
on carcinogenesis have not been fully clarifi ed and more de-
tailed studies are needed. 
In the present study, 28 patients had a diagnosis of cir-
rhosis prior to treatment, with two of them developing HCC 
22 and 64 months after SVR . Neither patient had detectable 
HCV-RNA in serum at the time of HCC diagnosis. Bruno et 
al.19 reported one case of HCC involving one cirrhotic pa-
tient in a series of 32 patients after SVR. Chavalitdhamrong 
et al.,18 in a study involving long-term follow-up of 171 pa-
tients with SVR – 27 of whom were cirrhotics before treat-
ment –, detected the development of HCC in 3 patients 14, 
18 and 29 months after discontinuation of antiviral treat-
ment. Two of them had a diagnosis of cirrhosis before the 
beginning of treatment.
Because of the risk, even though low, of the development 
of HCC in patients with cirrhosis due to HCV and with SVR, 
a regular follow-up of these patients is recommended with 
periodic abdominal ultrasound examination at six months 
intervals.17-19,30 The present data support this recommendation.
Except for the two cases of HCC, none of the patients 
with SVR in the present series presented any evidence of 
progression of liver disease assessed clinically and biochemi-
cally by routine tests (serum aminotransferases and liver 
function tests). Since there were no liver biopsies available 
during follow-up, our data do not contribute to the evalua-
tion of a possible histological improvement following SVR 
or of the possible persistence of intrahepatic HCV-RNA.
In conclusion, there was no recurrence of HCV infection 
in any of the 174 patients submitted to antiviral therapy who 
obtained SVR after a mean follow-up of 47 months (range: 
12 to156 months). In addition, there was no clinical or labo-
ratory evidence of liver disease progression after SVR, em-
phasizing the favourable long-term prognosis for patients 
who develop SVR. It should be pointed out that that disease 
decompensation did not occur in any of the patients with 
liver cirrhosis, although two of them developed HCC. This 
underscores the importance of early treatment of infection 
before severe liver damage sets in with the risk of progres-
sion to HCC, and the importance of continued HCC screen-
ing for patients who already have cirrhosis.
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